Stay updated with breaking news from Revascularization Device. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Penumbra (NYSE:PEN – Free Report) had its target price lifted by Wells Fargo & Company from $320.00 to $337.00 in a research note released on Wednesday, Marketbeat.com reports. The brokerage currently has an overweight rating on the stock. Several other analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft increased their target price on […]
Penumbra (NYSE:PEN – Free Report) had its target price cut by Truist Financial from $370.00 to $345.00 in a research report report published on Wednesday morning, MarketBeat reports. They currently have a buy rating on the stock. Several other equities analysts also recently weighed in on PEN. Citigroup raised their price objective on Penumbra from […]
Penumbra (NYSE:PEN – Get Free Report) had its target price lowered by analysts at Canaccord Genuity Group from $351.00 to $322.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 19.50% […]
Penumbra (NYSE:PEN – Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect Penumbra to post earnings of $0.28 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link. Penumbra (NYSE:PEN – Get Free […]
Penumbra (NYSE:PEN – Get Free Report) and H-CYTE (OTCMKTS:HCYTD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation. Insider and Institutional Ownership 91.1% of Penumbra shares are held […]